IN165717B - - Google Patents

Info

Publication number
IN165717B
IN165717B IN543/MAS/87A IN543MA1987A IN165717B IN 165717 B IN165717 B IN 165717B IN 543MA1987 A IN543MA1987 A IN 543MA1987A IN 165717 B IN165717 B IN 165717B
Authority
IN
India
Application number
IN543/MAS/87A
Other languages
English (en)
Inventor
Andrew Myers
Daniel Bichon
Original Assignee
Battelle Memorial Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Battelle Memorial Institute filed Critical Battelle Memorial Institute
Publication of IN165717B publication Critical patent/IN165717B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN543/MAS/87A 1986-08-07 1987-07-29 IN165717B (mo)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP86810347 1986-08-07
PCT/EP1987/000435 WO1988000837A2 (en) 1986-08-07 1987-08-05 Advanced anticancer therapy and cytotoxic medicaments for its implementation

Publications (1)

Publication Number Publication Date
IN165717B true IN165717B (mo) 1989-12-23

Family

ID=8196463

Family Applications (1)

Application Number Title Priority Date Filing Date
IN543/MAS/87A IN165717B (mo) 1986-08-07 1987-07-29

Country Status (10)

Country Link
US (1) US5087616A (mo)
EP (1) EP0259904B1 (mo)
JP (1) JPH01500435A (mo)
AU (1) AU608531B2 (mo)
CA (1) CA1323303C (mo)
DE (1) DE3770730D1 (mo)
DK (1) DK184788A (mo)
FI (1) FI881579A7 (mo)
IN (1) IN165717B (mo)
WO (1) WO1988000837A2 (mo)

Families Citing this family (310)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN165717B (mo) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US5529932A (en) * 1988-01-28 1996-06-25 Pharmacia, S.P.A. Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis
IL89220A (en) * 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
DE4004573A1 (de) * 1989-02-17 1990-08-23 Tanabe Seiyaku Co Neues versuchstier und seine herstellung
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5576288A (en) * 1989-04-27 1996-11-19 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
US5191067A (en) * 1989-04-27 1993-03-02 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
CA2032499C (en) * 1989-07-20 2002-05-14 Rainer Albert Polypeptide derivatives
US5208323A (en) * 1989-08-10 1993-05-04 Universite Laval Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
WO1991005799A1 (en) * 1989-10-23 1991-05-02 Schering Corporation Polypeptide inhibitors of gamma interferon
ES2155821T5 (es) * 1990-03-02 2008-04-16 Boston Medical Center Corporation Toxinas quimericas mejoradas.
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
ATE115864T1 (de) * 1990-05-30 1995-01-15 Deutsches Krebsforsch Polyethersubstituierte tumormittel.
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
CA2086679A1 (en) * 1990-07-05 1992-01-06 Hermanus A. M. Verheul Receptor directed-toxin conjugates
US5478804A (en) * 1990-09-19 1995-12-26 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
EP0510132B1 (en) * 1990-09-28 1997-05-14 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5431899A (en) * 1991-02-04 1995-07-11 University Of Saskatchewan Rotavirus VP6 as a diagnostic and targeting agent
US5464753A (en) * 1991-03-08 1995-11-07 Univ Illinois Purification and manipulation of bone marrow and blood cells on the basis of P-glycoprotein expression
DK0575545T3 (da) * 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
CA2102808A1 (en) * 1991-05-10 1992-11-11 Hanne Bentz Targeted delivery of bone growth factors
ES2075402T3 (es) * 1991-07-22 1995-10-01 Bracco Int Bv Conjugados quelados con metales paramagneticos para enfoque deliberado.
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
ES2149768T3 (es) * 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
DE69328092T2 (de) * 1992-05-28 2000-07-20 The University Of Toledo, Toledo Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial
US5679350A (en) * 1992-05-28 1997-10-21 The University Of Toledo Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
EP0646174A1 (en) * 1992-06-16 1995-04-05 The Whittier Institute For Diabetes And Endocrinology Recombinant production of saporin-containing proteins
US5393737A (en) * 1992-08-20 1995-02-28 Health Research, Inc. Cytotoxic drug conjugates for treatment of neoplastic diseases
WO1994005800A1 (en) * 1992-09-03 1994-03-17 The Regents Of The University Of California Dorsal tissue affecting factor and compositions
US5466672A (en) * 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
US6001364A (en) * 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly
ES2146649T3 (es) 1993-05-05 2000-08-16 Keith Rose Compuestos de polioximas y su preparacion.
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US6491905B1 (en) * 1993-09-14 2002-12-10 The Uab Research Foundation Recombinant bacterial cells for delivery of PNP to tumor cells
EP0648503B1 (en) * 1993-09-22 2000-07-26 Hoechst Aktiengesellschaft Pro-prodrugs, their production and use
US5962220A (en) * 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US7097839B1 (en) * 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
ES2237750T3 (es) * 1993-12-09 2005-08-01 Centro De Inmunologia Molecular Vacuna que comprende factor de crecimiento epidermico autologo humano y su uso.
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5911995A (en) * 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
DE4433890C2 (de) * 1994-09-22 1999-02-18 Deutsches Krebsforsch Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
PT788351E (pt) * 1994-11-10 2003-06-30 Univ Kentucky Res Foundation T Dispositivo implantavel recarregavel de libertacaocontrolada para administrar medicamentos direc tamente numa porcao interna do corpo
US5766899A (en) * 1995-02-27 1998-06-16 Board Of Regents , The University Of Texas System Targeted nucleic acid delivery into liver cells
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
DE69626849T2 (de) * 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
US20050025740A1 (en) * 1996-01-05 2005-02-03 Keith Rose Polyoxime compounds and their preparation
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DE69735057T2 (de) 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US5952294A (en) * 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US6080383A (en) * 1997-01-13 2000-06-27 Rose; Samuel Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
AU7124598A (en) * 1997-04-18 1998-11-13 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US5965118A (en) * 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds
EP0981545B1 (en) * 1997-05-05 2006-09-13 Mayo Foundation For Medical Education And Research IGFIIE/ IGFBP2 complex
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6548482B1 (en) 1997-05-05 2003-04-15 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
US6866837B2 (en) 1998-06-05 2005-03-15 Mallinckrodt Inc. Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
JP2002520369A (ja) * 1998-07-17 2002-07-09 アメリカ合衆国 水溶性薬剤およびその製造方法
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
GB9904582D0 (en) * 1999-02-26 1999-04-21 Nycomed Imaging As Process
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20010041189A1 (en) * 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
ES2548381T3 (es) 2000-03-27 2015-10-16 Thomas Jefferson University Composiciones para el tratamiento e imágenes de células de cáncer estomacales y de esófago
PL212211B1 (pl) 2000-06-02 2012-08-31 Regents Board Of Kompozycja do wytwarzania scyntygraficznego środka obrazującego, kompozycja do obrazowania scyntograficznego, sposób syntezy znakowanego radionuklidem koniugatu etylenodicysteiny z ligandem naprowadzającym do obrazowania, zastosowanie kompozycji zawierającej znakowany radionklidem konigat etylenodiscysteiny z ligandem naprowadzającym do wytwarzania środków farmaceutycznych do obrazowania nowotworu albo miejsca infekcji oraz zestaw do wytwarzania preparatów radiofarmaceutycznych
CA2414650A1 (en) * 2000-06-30 2002-01-10 Board Of Regents, The University Of Texas System Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
WO2002032400A1 (en) * 2000-10-16 2002-04-25 Neopharm, Inc. Liposomal formulation of mitoxantrone
US8394813B2 (en) * 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
JP2004536027A (ja) 2000-12-01 2004-12-02 ジョーンズ・ホプキンス・ユニーバーシティー グリコシル化／ガラクトシル化ペプチドの接合体、二官能性リンカー、およびヌクレオチドのモノマー／ポリマー、および関連する組成物および使用方法
CU22999A1 (es) 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
ATE333288T1 (de) * 2001-05-15 2006-08-15 Faulk Pharmaceuticals Inc Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen
JP2004532245A (ja) * 2001-05-15 2004-10-21 ページ ダブル フォーク 癌を治療するための生体影響性化合物の標的送達
EP1404692A1 (en) * 2001-06-22 2004-04-07 The University of British Columbia Antimitotic eleuthesides
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US20030109432A1 (en) * 2001-12-10 2003-06-12 Zuo William W. Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
RU2196604C1 (ru) * 2001-12-21 2003-01-20 Северин Евгений Сергеевич Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
CA2477038A1 (en) * 2002-02-22 2003-09-04 New River Pharmaceuticals Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
JP4878732B2 (ja) * 2002-02-22 2012-02-15 シャイア エルエルシー 規制物質の濫用を防ぐための新規な持続放出製薬化合物
AU2003270778B2 (en) 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
KR101086690B1 (ko) * 2002-11-07 2011-11-25 셀>포인트, 엘엘씨 에틸렌디시스테인（ｅｃ）－약물 콘쥬게이트, 조성물 및조직 특이적 질환 영상 방법
CA2524350C (en) 2003-05-07 2015-04-14 Indiana University Research & Technology Corporation Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto
BRPI0410792B8 (pt) * 2003-05-29 2021-05-25 New River Pharmaceuticals Inc compostos de anfetamina resistentes à dependencia
WO2005016368A2 (en) * 2003-08-19 2005-02-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of phosphophoryn for inducing biomineralization and bone regeneration
MXPA06003619A (es) * 2003-09-30 2008-01-14 New River Pharmaceuticals Inc Composiciones farmaceuticas para prevencion de sobredosis o abuso.
EP1675857B1 (en) 2003-10-22 2011-07-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
EP1694325A4 (en) 2003-12-03 2009-03-25 Univ New Jersey Med Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
PL1695991T3 (pl) * 2003-12-10 2010-05-31 Toudai Tlo Ltd Koordynacyjny kompleks diaminocykloheksanu platyny (II) z blokowym kopolimerem zawierającym fragment poli(kwasu karboksylowego), oraz środek przeciw-nowotworowy zawierający ten kompleks
EP1732949B1 (en) 2004-04-07 2010-01-27 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US20060036084A1 (en) * 2004-08-04 2006-02-16 Lianhua Qu Conglomerated semiconductor nanocrystals
US8454927B2 (en) * 2004-08-04 2013-06-04 Crystalplex Corporation Alloyed semiconductor nanocrystals
AU2006255938B2 (en) * 2005-06-09 2011-05-12 Nanocarrier Co., Ltd. Process for production of polymerized coordination compound of platinum complex
RU2303997C2 (ru) * 2005-09-27 2007-08-10 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Конъюгат, обладающий избирательным действием по отношению к раковым опухолям
WO2007055902A1 (en) * 2005-11-03 2007-05-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides and methods of use for treating and preventing cancer
BRPI0619436A2 (pt) 2005-12-05 2011-10-04 Nitto Denko Corp métodos e conjugados de aminoácido-poliglutamato
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
US9107863B2 (en) 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
RU2317102C1 (ru) * 2006-05-31 2008-02-20 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Пептид, являющийся аналогом фрагмента альфа-фетопротеина, конъюгат пептида с доксорубицином и фармацевтическая композиция на его основе для лечения онкологических заболеваний
DK2526932T3 (en) 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US8088379B2 (en) * 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
MY149170A (en) 2006-10-31 2013-07-31 Us Gov Health & Human Serv Smoothened polypeptides and methods of use
CA2674445C (en) 2007-01-12 2016-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101688229B (zh) 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
EP2144631A2 (en) * 2007-04-10 2010-01-20 Nitto Denko Corporation Multi-functional polyglutamate drug carriers
KR20100017540A (ko) 2007-05-09 2010-02-16 닛토덴코 가부시키가이샤 소수성 화합물 및 폴리아미노산 콘쥬게이트를 포함하는 조성물
JP2010526917A (ja) * 2007-05-09 2010-08-05 日東電工株式会社 複数種の薬物を有するポリグルタミン酸塩複合体及びポリグルタミン酸塩−アミノ酸複合体
CN101730549B (zh) * 2007-05-09 2015-12-09 日东电工株式会社 与铂类药物结合的聚合物
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
EP2188296A1 (en) * 2007-08-31 2010-05-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods
EP2262537A1 (en) * 2008-03-06 2010-12-22 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US9616245B2 (en) * 2009-03-16 2017-04-11 Rajah Vijay Kumar Method of treating cells with drug and radiation according to proton density
US8563513B2 (en) 2009-03-27 2013-10-22 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
US8603814B2 (en) * 2009-07-20 2013-12-10 Rutgers The State University Of New Jersey Method of inhibiting nonsense-mediated mRNA decay
US9849146B2 (en) 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
CA2776143A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US9127079B2 (en) 2009-10-16 2015-09-08 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (PTEN) conjugates
US20120208762A1 (en) 2009-10-27 2012-08-16 The Board Of Trustees Of The University Of Illinois Methods of Diagnosing Diastolic Dysfunction
WO2011060218A1 (en) 2009-11-13 2011-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulated programmed death ligand-1
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
EP2547359B1 (en) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibitors of beta integrin-g protein alpha subunit binding interactions
CA2811788C (en) 2010-09-21 2020-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-ssx-2 t cell receptors and related materials and methods of use
WO2012054825A1 (en) 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
CN102675422B (zh) 2011-03-15 2014-02-05 天津托普泰克生物科技有限公司 抗乙型肝炎病毒x蛋白多肽药物
PT3459560T (pt) 2011-04-08 2021-05-24 Us Health Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização dos mesmos para o tratamento de cancro
CN102746378B (zh) 2011-04-22 2014-10-22 天津托普泰克生物科技有限公司 抗脂肪酸合成酶多肽及其应用
CN103748107B (zh) 2011-06-09 2020-06-02 美利坚合众国, 由健康及人类服务部部长代表 具有免疫原性较小的t细胞和/或b细胞表位的假单胞菌外毒素a
WO2012177443A2 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CN109517055B (zh) 2011-09-15 2022-09-20 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体
EP3301110A1 (en) 2011-09-16 2018-04-04 The USA, as represented by The Secretary, Department of Health and Human Services Pseudomonas exotoxin a with less immunogenic b cell epitopes
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
CN103957927B (zh) 2011-11-17 2016-11-09 印第安纳大学研究及科技有限公司 呈现糖皮质激素受体活性的胰高血糖素超家族肽
US9359447B2 (en) 2012-03-23 2016-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
KR20240136359A (ko) 2012-04-11 2024-09-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
ES2718474T3 (es) 2012-05-22 2019-07-02 Us Health Receptores murinos de células T anti-NY-ESO-1
KR20150023729A (ko) 2012-06-14 2015-03-05 암브룩스, 인코포레이티드 핵 수용체 리간드 폴리펩티드에 접합된 항-psma 항체
EA029025B1 (ru) 2012-06-21 2018-01-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
WO2013192129A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
CN113754755A (zh) 2012-09-14 2021-12-07 美国政府卫生与公众服务部 识别mhc ii类限制性mage-a3的t细胞受体
CN110229834B (zh) 2012-10-24 2022-11-01 美国卫生和人力服务部 M971嵌合抗原受体
ES2949648T3 (es) 2012-12-20 2023-10-02 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US9890369B2 (en) 2013-06-20 2018-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
JP6584012B2 (ja) 2013-10-06 2019-10-02 アメリカ合衆国 改変シュードモナス外毒素ａ
CN105899531B (zh) 2013-12-06 2022-02-25 美国卫生和人力服务部 胸腺基质淋巴细胞生成素受体特异性的嵌合抗原受体及其使用方法
MA39867A (fr) 2014-04-23 2017-03-01 Juno Therapeutics Inc Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
IL290655B2 (en) 2014-05-29 2024-05-01 Us Health Anti-human papillomavirus 16 E7 T-cell chelates
EP3149044B1 (en) 2014-06-02 2020-10-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chimeric antigen receptors targeting cd-19
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
AU2015336029B2 (en) 2014-10-20 2021-07-22 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
FI3757206T3 (fi) 2014-11-05 2024-06-19 Juno Therapeutics Inc Menetelmiä transduktoimiseksi ja solun prosessoimiseksi
CN107206025A (zh) 2014-12-03 2017-09-26 朱诺治疗学股份有限公司 用于过继细胞治疗的方法和组合物
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
EP3303586A1 (en) 2015-05-29 2018-04-11 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
CA3002745A1 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
WO2017068425A1 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
RU2021134624A (ru) 2015-10-22 2022-03-15 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
WO2017096329A1 (en) 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
EP3384294B1 (en) 2015-12-04 2021-10-13 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
MA43759A (fr) 2016-03-16 2018-11-28 Jason Connor Procédés de conception adaptative d'un régime de traitement et traitements associés
EP3430548A1 (en) 2016-03-16 2019-01-23 Juno Therapeutics, Inc. Methods for determining dosing of a therapeutic agent and related treatments
MA71266A (fr) 2016-03-22 2025-04-30 Seattle Children's Hospital(DBA Seattle Children's Research Institute) Procédés d'intervention précoce pour prévenir ou améliorer la toxicité
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
KR20190038479A (ko) 2016-05-06 2019-04-08 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 및 그의 제조방법
EP4413999A3 (en) 2016-05-27 2024-08-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Flt3-specific chimeric antigen receptors and methods using same
CA3026453A1 (en) 2016-06-03 2017-12-07 Memorial Sloan-Kettering Cancer Center Adoptive cell therapies as early treatment options
CA3024725A1 (en) 2016-06-06 2017-12-14 Juno Therapeutics, Inc. Methods for the treatment of b cell malignancies using adoptive cell therapy
CN109937364B (zh) 2016-06-27 2022-12-02 朱诺治疗学股份有限公司 Mhc-e限制性表位、结合分子以及相关方法和用途
CN110291402B (zh) 2016-06-27 2023-09-01 朱诺治疗学股份有限公司 鉴定肽表位的方法、结合此类表位的分子和相关用途
US20190201414A1 (en) 2016-07-01 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
AU2017301880C1 (en) 2016-07-29 2022-04-21 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
CN110139873A (zh) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
CA3045323A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
CN110248678A (zh) 2016-12-03 2019-09-17 朱诺治疗学股份有限公司 调节car-t细胞的方法
CN110290807B (zh) 2016-12-03 2024-06-14 朱诺治疗学股份有限公司 确定car-t细胞给药的方法
JP2019536461A (ja) 2016-12-05 2019-12-19 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法のための操作細胞の産生
JP7429338B2 (ja) 2017-01-10 2024-02-08 ジュノー セラピューティクス インコーポレイテッド 細胞療法および関連方法のエピジェネティック解析
US11517627B2 (en) 2017-01-20 2022-12-06 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2018187791A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
JP2020522489A (ja) 2017-06-02 2020-07-30 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法を用いる処置のための製造物品および方法
WO2018223098A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
CN109517820B (zh) 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 一种靶向HPK1的gRNA以及HPK1基因编辑方法
MA50613A (fr) 2017-10-03 2020-08-12 Editas Medicine Inc Molécules de liaison spécifique à l'hpv
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
CA3081456A1 (en) 2017-11-01 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
EP4512823A3 (en) 2017-11-01 2025-05-14 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
BR112020008565A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc processo para a produção de uma composição de célula t
JP2021502077A (ja) 2017-11-06 2021-01-28 エディタス・メディシン，インコーポレイテッド 免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素
EP3716980A1 (en) 2017-12-01 2020-10-07 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
AU2018379094B2 (en) 2017-12-08 2025-09-25 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
CN112041430A (zh) 2017-12-08 2020-12-04 朱诺治疗学股份有限公司 用于培养细胞的无血清培养基配制品及其使用方法
KR20200110745A (ko) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
CN120154716A (zh) 2018-01-22 2025-06-17 恩多塞特公司 Car t细胞的使用方法
KR20200128014A (ko) 2018-01-31 2020-11-11 셀진 코포레이션 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
US20210046159A1 (en) 2018-03-09 2021-02-18 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
JP7630280B2 (ja) 2018-04-05 2025-02-17 ジュノー セラピューティクス インコーポレイテッド 組換え受容体を発現するｔ細胞、関連ポリヌクレオチド、および方法
US20210017249A1 (en) 2018-04-05 2021-01-21 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
US11471489B2 (en) 2018-04-05 2022-10-18 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
WO2020033916A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
WO2020043899A1 (en) 2018-08-31 2020-03-05 Invectys Chimeric antigen receptors against multiple hla-g isoforms
CN113227358A (zh) 2018-10-31 2021-08-06 朱诺治疗学有限公司 选择并刺激细胞的方法及用于所述方法的设备
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
MA54079A (fr) 2018-11-01 2021-09-08 Juno Therapeutics Inc Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
MX2021005021A (es) 2018-11-06 2021-08-11 Juno Therapeutics Inc Proceso para producir celulas t geneticamente modificadas.
KR20210104713A (ko) 2018-11-16 2021-08-25 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
BR112021010120A2 (pt) 2018-11-30 2021-08-31 Juno Therapeutics, Inc. Métodos para dosagem e tratamento de malignidades celulares em terapia celular adotiva
FI3886875T3 (fi) 2018-11-30 2024-07-23 Juno Therapeutics Inc Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
AU2020215576A1 (en) 2019-01-29 2021-07-08 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)
EP3952886A1 (en) 2019-04-10 2022-02-16 Elevatebio Technologies, Inc Flt3-specific chimeric antigen receptors and methods of using the same
CN113811329B (zh) 2019-04-19 2025-10-14 天科雅生物科技有限公司 抗pd-1抗体和其用途
SG11202111360YA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
WO2020223571A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
IL288284B2 (en) 2019-05-22 2024-06-01 Massachusetts Inst Technology Circular rna compositions and methods
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
BR112022008023A2 (pt) 2019-10-30 2022-07-12 Juno Therapeutics Gmbh Dispositivos de seleção e/ou estimulação de células e métodos de uso
EP4070097A1 (en) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
KR20220146480A (ko) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 형질도입 방법
AU2021251265A1 (en) 2020-04-10 2022-11-03 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
EP4150640A1 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
US20240042015A1 (en) 2020-05-19 2024-02-08 Orna Therapeutics, Inc. Circular rna compositions and methods
KR20230042283A (ko) 2020-06-26 2023-03-28 주노 테라퓨틱스 게엠베하 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
WO2022098787A1 (en) 2020-11-04 2022-05-12 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
EP4314814A1 (en) 2021-03-22 2024-02-07 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
KR20240112994A (ko) 2021-11-03 2024-07-19 셀진 코포레이션 골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
IL314801A (en) 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
EP4532731A2 (en) 2022-05-30 2025-04-09 Shanghai Circode Biomed Co., Ltd Synthetic circular rna compositions and methods of use thereof
EP4543923A1 (en) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
US20250382640A1 (en) 2022-06-29 2025-12-18 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
KR20250047766A (ko) 2022-08-05 2025-04-04 주노 쎄러퓨티크스 인코퍼레이티드 Gprc5d 및 bcma에 특이적인 키메라 항원 수용체
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024129778A2 (en) 2022-12-13 2024-06-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
AU2023398825A1 (en) 2022-12-15 2025-06-26 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
EP4705481A2 (en) 2023-05-05 2026-03-11 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE38892B1 (en) * 1973-03-28 1978-06-21 Ici Ltd Pharmaceutical compositions
EP0040506B1 (en) * 1980-05-21 1986-08-20 Teijin Limited Reactive polymer and process for the preparation thereof
IE53166B1 (en) * 1980-08-05 1988-08-03 Searle & Co Synthetic urogastrone gene,corresponding plasmid recombinants,transformed cells,production thereof and urogastrone expression
EP0108132A1 (en) * 1982-05-06 1984-05-16 Applied Molecular Genetics Inc. The manufacture and expression of genes for urogastrone and polypeptide analogs thereof
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
JPS58219124A (ja) * 1982-06-15 1983-12-20 Nippon Chem Res Kk ヒト上皮細胞増殖因子の製造法
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
JPS59116232A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体及びその製造法
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
JPS60501737A (ja) * 1983-07-05 1985-10-17 チロン　コ−ポレイシヨン 上皮成長因子のハイブリドｄｎａ合成
JPS6028994A (ja) * 1983-07-08 1985-02-14 Wakunaga Seiyaku Kk 〔２１―ロイシン〕ヒトウロガストロン
IL69719A0 (en) * 1983-09-14 1983-12-30 Yeda Res & Dev Synthetic peptides with egf like activity
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4522750A (en) * 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
CA1283661C (en) * 1984-06-20 1991-04-30 Franz Jansen Imidazolides, process for their preparation and application as intermediates for the synthesis of cytotoxic conjugates
IN165717B (mo) * 1986-08-07 1989-12-23 Battelle Memorial Institute

Also Published As

Publication number Publication date
US5087616A (en) 1992-02-11
DE3770730D1 (de) 1991-07-18
WO1988000837A2 (en) 1988-02-11
JPH01500435A (ja) 1989-02-16
FI881579A0 (fi) 1988-04-06
DK184788A (da) 1988-06-06
AU608531B2 (en) 1991-04-11
FI881579L (fi) 1988-04-06
DK184788D0 (da) 1988-04-06
EP0259904A1 (en) 1988-03-16
FI881579A7 (fi) 1988-04-06
WO1988000837A3 (en) 1988-03-10
CA1323303C (en) 1993-10-19
EP0259904B1 (en) 1991-06-12
AU7788787A (en) 1988-02-24

Similar Documents

Publication Publication Date Title
US4736817B1 (mo)
IN165717B (mo)
IN170338B (mo)
IN165073B (mo)
GR3003618T3 (mo)
US4711958B1 (mo)
IN165466B (mo)
GR3005686T3 (mo)
DE3790178T1 (mo)
IN171087B (mo)
IN168030B (mo)
IN167698B (mo)
IN168419B (mo)
AU5753186A (mo)
BE905826A (mo)
AU5783386A (mo)
IN166480B (mo)
AU5767086A (mo)
IN163957B (mo)
IN169785B (mo)
AU5614386A (mo)
AU5614486A (mo)
AU5644686A (mo)
DE3790278T1 (mo)
BE905208A (mo)